An Economic Analysis of the Survival and Ventricular Enlargement (SAVE) Study
- 1 August 1997
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 12 (2), 182-192
- https://doi.org/10.2165/00019053-199712020-00008
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Cost‐effectiveness: a new criterion for selecting therapyJournal of Internal Medicine, 1995
- Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.Circulation, 1994
- Costs and Effectiveness of Angiotensin Converting Enzyme Inhibition in Patients With Congestive Heart FailureArchives of Internal Medicine, 1994
- GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.1994
- Effects of ACE Inhibitors on Heart Failure in The NetherlandsPharmacoEconomics, 1993
- Some guidelines on the use of cost effectiveness league tables.BMJ, 1993
- Assessing the economic value of antihypertensive medicines.1992
- Cost effective analyses in the treatment of high blood pressure.1992
- Discounting of Health Benefits in the Pharmacoeconomic Analysis of Drug TherapiesPharmacoEconomics, 1992
- Discounting and health benefits: Another PerspectiveHealth Economics, 1992